Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
The action mechanism of compound K on MRSA and VRE was investigated. Compound K inhibited topoisomerase IV of Staphylococcus aureus. However, this action mechanism was different from both ciprofloxacin and novobiocin, already known inhibitors of topoisomerase IV. Compound K also showed the combined effect with vancomycin. Expression of vancomycin resistant cluster genes was not inhibited with compound K, and exposure to compound K restored D-alanyl-D-alanine in VRE cells.
|